Profiling bladder cancer organ site-specific metastasis identifies LAMC2 as a novel biomarker of hematogenous dissemination

Steven Christopher Smith, Brian Nicholson, Matthew Nitz, Henry F. Frierson, Mark Smolkin, Garret Hampton, Wael El-Rifai, Dan Theodorescu

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Little is known about which genes mediate metastasis in bladder cancer, which accounts for much of the mortality of this disease. We used human bladder cancer cell lines to develop models of two clinically common metastatic sites, lung and liver, and evaluated their gene expression with respect to human tumor tissues. Parental cells were injected into either the murine spleen to generate liver metastases or tail vein to generate lung metastases with sequential progeny derived by re-injection and comparisons made of their organ-specific nature by crossed-site injections. Both genomic and transcriptomic analyses of organ-selected cell lines found salient differences and shared core metastatic profiles, which were then screened against gene expression data from human tumors. The expression levels of laminin V gamma 2 (LAMC2) contained in the core metastatic signature were increased as a function of human tumor stage, and its genomic location was in an area of gain as measured by comparative genomic hybridization. Using immunohistochemistry in a human bladder cancer tissue microarray, LAMC2 expression levels were associated with tumor grade, but inversely with nodal status. In contrast, in node-negative patients, LAMC2 expression was associated with visceral metastatic recurrence. In summary, LAMC2 is a novel biomarker of bladder cancer metastasis that reflects the propensity of cells to metastasize via either lymphatic or hematogenous routes.

Original languageEnglish (US)
Pages (from-to)371-379
Number of pages9
JournalAmerican Journal of Pathology
Volume174
Issue number2
DOIs
StatePublished - Jan 1 2009
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Biomarkers
Neoplasm Metastasis
Neoplasms
Gene Expression
Cell Line
Lung
Injections
Comparative Genomic Hybridization
Liver
Laminin
Tail
Veins
Spleen
Immunohistochemistry
Recurrence
Mortality
Genes

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Smith, S. C., Nicholson, B., Nitz, M., Frierson, H. F., Smolkin, M., Hampton, G., ... Theodorescu, D. (2009). Profiling bladder cancer organ site-specific metastasis identifies LAMC2 as a novel biomarker of hematogenous dissemination. American Journal of Pathology, 174(2), 371-379. https://doi.org/10.2353/ajpath.2009.080538

Profiling bladder cancer organ site-specific metastasis identifies LAMC2 as a novel biomarker of hematogenous dissemination. / Smith, Steven Christopher; Nicholson, Brian; Nitz, Matthew; Frierson, Henry F.; Smolkin, Mark; Hampton, Garret; El-Rifai, Wael; Theodorescu, Dan.

In: American Journal of Pathology, Vol. 174, No. 2, 01.01.2009, p. 371-379.

Research output: Contribution to journalArticle

Smith, Steven Christopher ; Nicholson, Brian ; Nitz, Matthew ; Frierson, Henry F. ; Smolkin, Mark ; Hampton, Garret ; El-Rifai, Wael ; Theodorescu, Dan. / Profiling bladder cancer organ site-specific metastasis identifies LAMC2 as a novel biomarker of hematogenous dissemination. In: American Journal of Pathology. 2009 ; Vol. 174, No. 2. pp. 371-379.
@article{75b8d5eb54b44d38ae090580e86f020f,
title = "Profiling bladder cancer organ site-specific metastasis identifies LAMC2 as a novel biomarker of hematogenous dissemination",
abstract = "Little is known about which genes mediate metastasis in bladder cancer, which accounts for much of the mortality of this disease. We used human bladder cancer cell lines to develop models of two clinically common metastatic sites, lung and liver, and evaluated their gene expression with respect to human tumor tissues. Parental cells were injected into either the murine spleen to generate liver metastases or tail vein to generate lung metastases with sequential progeny derived by re-injection and comparisons made of their organ-specific nature by crossed-site injections. Both genomic and transcriptomic analyses of organ-selected cell lines found salient differences and shared core metastatic profiles, which were then screened against gene expression data from human tumors. The expression levels of laminin V gamma 2 (LAMC2) contained in the core metastatic signature were increased as a function of human tumor stage, and its genomic location was in an area of gain as measured by comparative genomic hybridization. Using immunohistochemistry in a human bladder cancer tissue microarray, LAMC2 expression levels were associated with tumor grade, but inversely with nodal status. In contrast, in node-negative patients, LAMC2 expression was associated with visceral metastatic recurrence. In summary, LAMC2 is a novel biomarker of bladder cancer metastasis that reflects the propensity of cells to metastasize via either lymphatic or hematogenous routes.",
author = "Smith, {Steven Christopher} and Brian Nicholson and Matthew Nitz and Frierson, {Henry F.} and Mark Smolkin and Garret Hampton and Wael El-Rifai and Dan Theodorescu",
year = "2009",
month = "1",
day = "1",
doi = "10.2353/ajpath.2009.080538",
language = "English (US)",
volume = "174",
pages = "371--379",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Profiling bladder cancer organ site-specific metastasis identifies LAMC2 as a novel biomarker of hematogenous dissemination

AU - Smith, Steven Christopher

AU - Nicholson, Brian

AU - Nitz, Matthew

AU - Frierson, Henry F.

AU - Smolkin, Mark

AU - Hampton, Garret

AU - El-Rifai, Wael

AU - Theodorescu, Dan

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Little is known about which genes mediate metastasis in bladder cancer, which accounts for much of the mortality of this disease. We used human bladder cancer cell lines to develop models of two clinically common metastatic sites, lung and liver, and evaluated their gene expression with respect to human tumor tissues. Parental cells were injected into either the murine spleen to generate liver metastases or tail vein to generate lung metastases with sequential progeny derived by re-injection and comparisons made of their organ-specific nature by crossed-site injections. Both genomic and transcriptomic analyses of organ-selected cell lines found salient differences and shared core metastatic profiles, which were then screened against gene expression data from human tumors. The expression levels of laminin V gamma 2 (LAMC2) contained in the core metastatic signature were increased as a function of human tumor stage, and its genomic location was in an area of gain as measured by comparative genomic hybridization. Using immunohistochemistry in a human bladder cancer tissue microarray, LAMC2 expression levels were associated with tumor grade, but inversely with nodal status. In contrast, in node-negative patients, LAMC2 expression was associated with visceral metastatic recurrence. In summary, LAMC2 is a novel biomarker of bladder cancer metastasis that reflects the propensity of cells to metastasize via either lymphatic or hematogenous routes.

AB - Little is known about which genes mediate metastasis in bladder cancer, which accounts for much of the mortality of this disease. We used human bladder cancer cell lines to develop models of two clinically common metastatic sites, lung and liver, and evaluated their gene expression with respect to human tumor tissues. Parental cells were injected into either the murine spleen to generate liver metastases or tail vein to generate lung metastases with sequential progeny derived by re-injection and comparisons made of their organ-specific nature by crossed-site injections. Both genomic and transcriptomic analyses of organ-selected cell lines found salient differences and shared core metastatic profiles, which were then screened against gene expression data from human tumors. The expression levels of laminin V gamma 2 (LAMC2) contained in the core metastatic signature were increased as a function of human tumor stage, and its genomic location was in an area of gain as measured by comparative genomic hybridization. Using immunohistochemistry in a human bladder cancer tissue microarray, LAMC2 expression levels were associated with tumor grade, but inversely with nodal status. In contrast, in node-negative patients, LAMC2 expression was associated with visceral metastatic recurrence. In summary, LAMC2 is a novel biomarker of bladder cancer metastasis that reflects the propensity of cells to metastasize via either lymphatic or hematogenous routes.

UR - http://www.scopus.com/inward/record.url?scp=59649113022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59649113022&partnerID=8YFLogxK

U2 - 10.2353/ajpath.2009.080538

DO - 10.2353/ajpath.2009.080538

M3 - Article

C2 - 19147813

AN - SCOPUS:59649113022

VL - 174

SP - 371

EP - 379

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 2

ER -